Durability of Atrial Linear Lesion Sets with a Dual-Energy Lattice-Tip Catheter
Authors, Journal, Affiliations, Type, DOI
- Authors: Moritz Nies, Maria Luisa Benesch Vidal, Ilaria My, Marc D. Lemoine, Katharina Govorov, Niklas Schenker, Djemail Ismaili, Johanna Skibowski, Dominik Christmann, Lea Scharlemann, Bruno Reißmann, Feifan Ouyang, Paulus Kirchhof, Andreas Rillig, and Andreas Metzner
- Affiliations: Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf; German Center for Cardiovascular Research (DZHK), Partner Site North
- Journal: Heart Rhythm, volume 23, number 10, October 2026, pages 2114–2122
- Type: Retrospective, single-centre observational analysis of invasive remapping data (quality-control registry, ethics approval AZ 2025-300655-WF)
- DOI: 10.1016/j.hrthm.2026.05.004
- Funding: None specific. Several senior authors (Rillig, Metzner) report Medtronic consulting and lecture relationships stated as unrelated to the study; two Medtronic employees are acknowledged for technical support and data acquisition
Overview
This study reports invasive remapping of left-atrial linear lesions created with the dual-energy lattice-tip (Sphere-9) catheter, which can toggle between radiofrequency and pulsed field energy. Of 252 patients treated, 39 (16%) returned for a repeat procedure, allowing 36 pulmonary veins and 71 linear lesions to be reassessed. Posterior-wall lesions created with pulsed field alone were completely durable — roof lines 6/6 and posterior box lesions 10/10 — as were all 7 cavotricuspid isthmus lines made with radiofrequency. Anterior lines (9/17, 53%) and mitral isthmus lines (7/13, 54%) were not, reconnecting at roughly the rate reported for conventional thermal ablation. The striking result is therefore narrow: adding PFA to the lattice tip has solved the posterior wall, where oesophageal proximity limited thermal energy, and has not solved the anterior wall or mitral isthmus, where the obstacle is myocardial thickness and anatomy rather than heat.
Keywords
Atrial fibrillation, catheter ablation, pulsed field ablation, radiofrequency ablation, lattice-tip catheter, dual-energy ablation, linear ablation, lesion durability, posterior wall isolation, mitral isthmus, cavotricuspid isthmus
Key Takeaways
Rationale
- Antral pulmonary vein isolation is the mainstay; atrial linear lesions are added adjunctively and are established therapy for macro-reentrant atrial tachycardia
- Linear lesion durability has been poor with conventional thermal ablation, because anatomy limits catheter access and stability, radiofrequency may be insufficient for thick myocardium, and proximity to non-myocardial structures limits energy delivery
- Pulsed field ablation offers non-thermal, relatively tissue-specific ablation that overcomes some of these limits, and the 9-mm lattice tip can deliver either energy
- Durability matters especially for PFA because reversible electroporation can produce transient stunning that mimics successful ablation acutely
Design
- Single high-volume German centre; all patients treated with the Sphere-9 (Medtronic) lattice-tip catheter for left-atrial ablation were screened for remapping data
- Procedure A = the index ablation with the lattice tip; Procedure B = any repeat intervention between April 2023 and February 2026 that included 3D remapping of those lesions
- Only de novo lesions created in Procedure A were analysed, to avoid confounding by earlier ablation
- Ablation settings: temperature-controlled RF at 73 °C for 5 s; biphasic monopolar PFA in 4-second endocardial applications; target hottest-to-hottest electrode spacing 4–5 mm for PFA and 7–8 mm for RF; activated clotting time >350 s throughout
- Lesion definitions and energy:
- Roof line (right to left superior PV): PFA only
- Posterior box (roof plus an inferior line between the inferior PVs): PFA only
- Anterior line (lateral mitral annulus to the anterior RSPV): RF at the annulus, switching to PFA near the RSPV to protect the phrenic nerve
- Mitral isthmus line (posterior mitral annulus to the inferior ridge between LPV and LAA): RF first, PFA stacked as needed; in 2 cases PFA was delivered from the coronary sinus using a dedicated 1-second setting
- CTI line: RF only
- Durability definitions in Procedure B: entrance block for PVs; conduction block for roof, anterior, mitral and CTI lines; elimination of electrical activity within the box. Where Procedure B was performed for LAA occlusion after prior LAA isolation, durable LAA isolation was accepted as evidence of both anterior and mitral line block
- Remapping used conventional 3D systems (Carto 3, EnSite) in all but 4 cases, which used the Affera system again
Cohort
- 252 patients treated; 39 (16%) remapped
- Median age 74 years (IQR 61–78); 41% female; median LVEF 60% (45–60); median CHA₂DS₂-VASc 3 (1–4)
- 77% persistent AF; 44% with concomitant atrial tachycardia
- Median LA volume 170 ml; median LAVI 82.4 ml/m² (74.1–101.4)
- Indication for Procedure B: arrhythmia recurrence in 14 (36%); scheduled LAA occlusion after previous LAA isolation in 25 (64%)
- The two indications are different populations. Patients returning for LAA occlusion had far more prior ablation (96% vs 50%; P = .001), a higher LAVI (94.3 vs 76.7 ml/m²; P = .045), and a much shorter interval from Procedure A (37 days, IQR 29–57) than those returning for recurrence (208 days in Table 1, 308 days in the text, IQR 80–557; P = .003 — the two passages disagree)
- 120 lesions were created in Procedure A, of which 89 (74%) were de novo; acute success was 18/18 (100%) for PVI and 70/71 (99%) for linear lesions
Durability Results
| Lesion | Durable / reassessed | Durability | Energy | Median days to remap |
|---|---|---|---|---|
| Pulmonary veins | 31/36 | 86% | PFA only | 199 (102–579) |
| Roof line | 6/6 | 100% | PFA only | 564 (175–834) |
| Posterior box | 10/10 | 100% | PFA only | 58 (35–175) |
| Anterior line | 9/17 | 53% | RF + PFA | 46 (35–81) |
| Mitral isthmus | 7/13 | 54% | RF ± PFA | 35 (29–67) |
| Cavotricuspid isthmus | 7/7 | 100% | RF only | 43 (34–175) |
| All linear lesions | 54/71 | 76% | — | — |
- All right-sided PVs were durably isolated; the three left-PV reconductions involved the ridge, the anterior aspect and the inferior/anterior LIPV
- No procedural parameter predicted durability for any lesion type — ablation time, total applications, PFA applications and RF applications were all similar between durable and reconnected lesions
- In the 14 patients presenting with recurrence, 24 of 30 (80%) re-assessed de novo lesions were durable; the six non-durable lesions (3 LPVs, 3 anterior lines) were all re-ablated
Procedural Data
- Skin-to-skin procedure time 97 ± 31 minutes; mapping 17 ± 8 minutes over 3,978 ± 1,317 points; LA map volume 173 ± 35 ml
- Roof line: 5 applications (3–7), 1 minute (1–2) — the shortest lesion on the list
- Posterior box: 26 applications (20–32), 8 minutes (7–9)
- Anterior line: 16 RF (14–19) plus 5 PFA (4–23), 12 minutes (6–16)
- Mitral isthmus: 15 RF (13–19) plus 8 PFA (5–15), 10 minutes (8–18); RF-only in 1 of 13 (8%), combined in 12 (92%)
- CTI: 8 applications (7–13), 2 minutes (2–6)
- No coronary artery spasm occurred during any mitral isthmus ablation
- One mitral line could not be acutely blocked in a patient with a previous surgical mitral valve repair and a persistent left superior vena cava, despite 14 RF and 40 PFA applications including 8 from the coronary sinus; one further mitral line could not be reassessed because the recurrent tachycardia was right-sided and no left-atrial access was obtained
Context from Other Remapping Studies
- Posterior wall with thermal energy was the comparator problem: in CAPLA, acute posterior-wall isolation succeeded in 86.4% but durable isolation at re-ablation after 1.4 years was only 25%; a MANIFEST sub-analysis found 46% durable posterior-wall isolation with the pentaspline PFA catheter, in patients selected by recurrence
- PVI: SPHERE Per-AF re-ablation found 67% durability at 12 months; Reddy et al. reported 99.1% at protocol-mandated remapping 108 days after RF-only lattice-tip ablation
- Mitral isthmus: conventional RF durability is 33–51%; a previous lattice-tip remapping study reported 68% at 96 days with different waveforms and a steerable sheath in 94%; Reddy et al. reported 91% with RF alone
- Anterior line: prior remapping series report 42–50%, in patients selected by arrhythmia recurrence
Interpretation
- The authors' three conclusions: posterior-wall lesions with PFA are highly durable; anterior and mitral isthmus lines remain difficult even with a catheter that can toggle energy, with reconnection up to 47%; and PFA-based PVI with RF-based CTI is highly durable
- Their mechanistic reading: the mitral isthmus and the anterior line cross thick atrial myocardium intersected by connective tissue strands, near the LAA junction — anatomical features that energy choice does not overcome
- They propose that if the posterior-wall durability is confirmed, a trial akin to CAPLA could be repeated without the confounding of non-transmural RF lesions, and note a SPHERE Per-AF sub-analysis showing a trend toward better outcomes when linear lesions were added
- Proposed routes to better anterior and mitral durability: workflow optimisation, PFA from the coronary sinus, sequential rather than simultaneous RF and PFA along the line, and longer intraprocedural waiting times before testing block
Limitations of the document
- Only 16% of treated patients were remapped, and the indication for remapping determines what is found. Two-thirds returned for a planned LAA occlusion rather than for arrhythmia, and lesion types were not independently sampled — posterior box and CTI lesions were not reassessed at all in patients with durable LAA isolation, so the denominators differ by lesion and by patient
- The comparison between lesion types is confounded by follow-up time, and in opposite directions. Roof-line durability (100%) was assessed at a median of 564 days, which is a genuinely strong result; posterior box durability (100%) was assessed at a median of 58 days, which is early enough that some of it could still reconduct. Conversely, anterior (46 days) and mitral (35 days) lines were assessed so early that reversible electroporation stunning or oedema could account for part of the apparent failure — a mechanism the authors themselves raise
- The two populations differ systematically: the LAA-occlusion group had more prior ablation and much larger atria, both of which plausibly increase reconnection
- Retrospective, single-centre, small numbers. Some lesion categories rest on 6–10 observations, and the confidence intervals around 100% are wide
- The steerable sheath was used at operator discretion and was not standardised — the authors note that most mitral isthmus cases used a fixed-curve sheath, which may have limited lesion quality and is a plausible confounder of the mitral result
- Maps from Procedures A and B were created with different software and were not comparable in all cases, so a systematic analysis of where gaps arose relative to the original applications was not possible
- The reference standard is conduction block assessed by activation mapping and differential pacing, not pathological lesion assessment
- Manufacturer relationships: the device manufacturer provided technical support and data acquisition assistance, and several authors report consulting and lecture relationships with Medtronic
Key Concepts Mentioned
- concepts/PFA-Atrial-Arrhythmias — lesion durability beyond the pulmonary veins is the field's central open problem, and this is the first remapping dataset for the lattice tip
- concepts/Catheter-Ablation-AF — where linear lesions sit in the ablation strategy for persistent AF and atrial tachycardia
- concepts/Pulsed-Field-Ablation — the modality and its tissue selectivity
- concepts/Structural-Valve-Deterioration — not addressed, but LAA isolation and occlusion were the reason two-thirds of these patients were remapped
- concepts/Atrial-Cardiomyopathy — the substrate that makes linear lesions necessary in persistent AF
Key Entities Mentioned
- entities/Sphere-9 — the dual-energy lattice-tip catheter under study
- Medtronic — manufacturer; provided technical support. No separate entity page is warranted
- entities/Atrial-Fibrillation — the disease treated
Wiki Pages Updated
wiki/sources/sphere9-linear-durability-hrs-2026.md— created (this page)wiki/entities/Sphere-9.md— atrial linear-lesion durability section and one contradiction addedwiki/concepts/PFA-Atrial-Arrhythmias.md— redo-durability section and the applications table updated; one contradiction addedwiki/concepts/Catheter-Ablation-AF.md— lesion-set bullet addedwiki/sourceindex.md— index rowwiki/wikiindex.md— Sphere-9 and PFA rows revisedlog.md— ingest entry